The role of glucagon-like peptide 1 (GLP-1) in addictive disorders

Research output: Contribution to journal › Review › Research › peer-review

Standard

The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. / Kruse Klausen, Mette; Thomsen, Morgane; Wortwein, Gitta; Fink-Jensen, Anders.

In: British Journal of Pharmacology, Vol. 179, No. 4, 2022, p. 625-641.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Kruse Klausen, M, Thomsen, M, Wortwein, G & Fink-Jensen, A 2022, 'The role of glucagon-like peptide 1 (GLP-1) in addictive disorders', British Journal of Pharmacology, vol. 179, no. 4, pp. 625-641. https://doi.org/10.1111/bph.15677

APA

Kruse Klausen, M., Thomsen, M., Wortwein, G., & Fink-Jensen, A. (2022). The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. British Journal of Pharmacology, 179(4), 625-641. https://doi.org/10.1111/bph.15677

Vancouver

Kruse Klausen M, Thomsen M, Wortwein G, Fink-Jensen A. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. British Journal of Pharmacology. 2022;179(4):625-641. https://doi.org/10.1111/bph.15677

Author

Kruse Klausen, Mette ; Thomsen, Morgane ; Wortwein, Gitta ; Fink-Jensen, Anders. / The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. In: British Journal of Pharmacology. 2022 ; Vol. 179, No. 4. pp. 625-641.

Bibtex

@article{02d46fdeeb8741db98038506578c5d20,
title = "The role of glucagon-like peptide 1 (GLP-1) in addictive disorders",
abstract = "Drug, alcohol and tobacco use disorders are a global burden affecting millions of people. Despite decades of research, treatment options are sparse or missing, and relapse rates are high. Glucagon-like peptide 1 (GLP-1) is released in the small intestine, promotes blood glucose homeostasis, slows gastric emptying and reduces appetite. GLP-1 receptor agonists approved for treating Type 2 diabetes mellitus and obesity have received attention as a potential anti-addiction treatment. Studies in rodents and non-human primates have demonstrated a reduction in intake of alcohol and drugs of abuse, and clinical trials have been initiated to investigate whether the preclinical findings can be translated to patients. This review will give an overview of current findings and discuss the possible mechanisms of action. We suggest that effects of GLP-1 in alcohol and substance use disorders is mediated centrally, at least partly through dopamine signalling, but precise mechanisms are still to be uncovered.",
keywords = "addiction, alcohol, alcohol use disorder, amphetamine, cocaine, dopamine, GLP-1, glucagon-like peptide-1, nicotine, opioids, substance use disorder, tobacco, WITHDRAWAL-INDUCED ANXIETY, VENTRAL TEGMENTAL AREA, NUCLEUS-ACCUMBENS, RECEPTOR AGONISTS, CONCISE GUIDE, FOOD-INTAKE, MESSENGER-RNAS, ALCOHOL, COCAINE, EXENDIN-4",
author = "{Kruse Klausen}, Mette and Morgane Thomsen and Gitta Wortwein and Anders Fink-Jensen",
year = "2022",
doi = "10.1111/bph.15677",
language = "English",
volume = "179",
pages = "625--641",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley",
number = "4",

}

RIS

TY - JOUR

T1 - The role of glucagon-like peptide 1 (GLP-1) in addictive disorders

AU - Kruse Klausen, Mette

AU - Thomsen, Morgane

AU - Wortwein, Gitta

AU - Fink-Jensen, Anders

PY - 2022

Y1 - 2022

N2 - Drug, alcohol and tobacco use disorders are a global burden affecting millions of people. Despite decades of research, treatment options are sparse or missing, and relapse rates are high. Glucagon-like peptide 1 (GLP-1) is released in the small intestine, promotes blood glucose homeostasis, slows gastric emptying and reduces appetite. GLP-1 receptor agonists approved for treating Type 2 diabetes mellitus and obesity have received attention as a potential anti-addiction treatment. Studies in rodents and non-human primates have demonstrated a reduction in intake of alcohol and drugs of abuse, and clinical trials have been initiated to investigate whether the preclinical findings can be translated to patients. This review will give an overview of current findings and discuss the possible mechanisms of action. We suggest that effects of GLP-1 in alcohol and substance use disorders is mediated centrally, at least partly through dopamine signalling, but precise mechanisms are still to be uncovered.

AB - Drug, alcohol and tobacco use disorders are a global burden affecting millions of people. Despite decades of research, treatment options are sparse or missing, and relapse rates are high. Glucagon-like peptide 1 (GLP-1) is released in the small intestine, promotes blood glucose homeostasis, slows gastric emptying and reduces appetite. GLP-1 receptor agonists approved for treating Type 2 diabetes mellitus and obesity have received attention as a potential anti-addiction treatment. Studies in rodents and non-human primates have demonstrated a reduction in intake of alcohol and drugs of abuse, and clinical trials have been initiated to investigate whether the preclinical findings can be translated to patients. This review will give an overview of current findings and discuss the possible mechanisms of action. We suggest that effects of GLP-1 in alcohol and substance use disorders is mediated centrally, at least partly through dopamine signalling, but precise mechanisms are still to be uncovered.

KW - addiction

KW - alcohol

KW - alcohol use disorder

KW - amphetamine

KW - cocaine

KW - dopamine

KW - GLP-1

KW - glucagon-like peptide-1

KW - nicotine

KW - opioids

KW - substance use disorder

KW - tobacco

KW - WITHDRAWAL-INDUCED ANXIETY

KW - VENTRAL TEGMENTAL AREA

KW - NUCLEUS-ACCUMBENS

KW - RECEPTOR AGONISTS

KW - CONCISE GUIDE

KW - FOOD-INTAKE

KW - MESSENGER-RNAS

KW - ALCOHOL

KW - COCAINE

KW - EXENDIN-4

U2 - 10.1111/bph.15677

DO - 10.1111/bph.15677

M3 - Review

C2 - 34532853

VL - 179

SP - 625

EP - 641

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 4

ER -

ID: 291676532